Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate

Translational Research

Volumn 149, Issue 5, 2007, Pages 260-264

  Hou, Guoqing ^a   Dick, Robert ^a   Zeng, Chunhua ^a   Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; COPPER; DOXORUBICIN; TETRATHIOMOLYBDIC ACID; TETRATHIOTUNGSTIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; HEART PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 34247390046     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.12.003     Document Type: Article

References (20)

1. Brewer G.J., Dick R.D., Yuzbasiyan-Gurkan V., Tankanow R., Young A.B., and Kluin K.J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48 (1991) 42-47
2. Brewer G.J., Dick R.D., Johnson V., Wang Y., Yuzbasiyan-Gurkan V., Kluin K., et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51 (1994) 545-554
3. Brewer G.J., Johnson V., Dick R.D., Kluin K.J., Fink J.K., and Brunberg J.A. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53 (1996) 1017-1025
4. Brewer G.J., Hedera P., Kluin K.J., Carlson M., Askari F., Dick R.B., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
5. Brewer G.J., Askari F., Lorincz M.T., Carlson M., Schilsky M., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63 (2006) 521-527
6. Cox C., Merajver S.D., Yoo S., Dick R.D., Brewer G.J., Lee J.S., et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 129 (2003) 781-785
7. Cox C.D., Teknos T.N., Barrios M., Brewer G.J., Dick R.D., and Merajver S.D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111 (2001) 696-701
8. Kent M.S., Madewell B.R., Dank G., Dick R.B., Merajver S.D., and Brewer G.J. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: a pilot study in a canine animal mode. J Trace Elem Exp Med 17 (2004) 9-20
9. Khan M.K., Miller M.W., Taylor J., Gill N.K., Dick R.D., Van Golen K.L., et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4 (2002) 164-170
10. Pan Q., Bao L.W., Kleer C.G., Brewer G.J., and Merajver S.D. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2 (2003) 617-622
11. Pan Q., Kleer C.G., Van Golen K.L., Irani J., Bottema K.M., Bias C., et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62 (2002) 4854-4859
12. Van Golen K.L., Bao L., Brewer G.J., Pienta K.J., Kamradt J.M., Livant D.L., et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4 (2002) 373-379
13. Brewer G.J., Ullenbruch M.R., Dick R.B., Olivarez L., and Phan S.H. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141 (2003) 210-216
14. Brewer G.J., Dick R., Ullenbruch M.R., Jin H., and Phan S.H. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98 (2004) 2160-2167
15. Askari F.K., Dick R.B., Mao M., and Brewer G.J. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229 (2004) 857-863
16. Ma S., Hou G., Dick R.D., and Brewer G.J. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4 (2004) 419-426
17. Hou G., Dick R., Abrams G.D., and Brewer G.J. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146 (2005) 299-303
18. McQuaid A., Lamand M., and Mason J. Thiotungstate-copper interactions II. The effects of tetrathiotungstate on systemic copper metabolism in normal and copper-treated rats. J Inorg Biochem 53 (1994) 205-218
19. Young B.W., Bremner I., and Mills C.F. Effects of tetrathiotungstate and dithiotungstate on copper metabolism in rats. J Inorg Biochem 16 (1982) 121-134
20. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25 (1998) 10-14